Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ranibizumab 0.5mg (monthly) Clear all
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

NCT01003106
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
Drug · Procedure
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

NCT01077401
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT06190093
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
61
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2Phase 3 Interventional

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

NCT00590694
View directory record Official record
Conditions
Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Pacific Eye Associates
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration

NCT02510794
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

NCT00680225
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
Ranibizumab injection and TTT - ICG based
Drug
Lead sponsor
New England Retina Associates
Other
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Hamden, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

NCT01748292
View directory record Official record
Conditions
Macular Degeneration
Interventions
0.5 mg ranibizumab
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

NCT00765921
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
ranibizumab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 1Phase 2 Interventional

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

NCT00440609
View directory record Official record
Conditions
Clinically Significant Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Philip J. ferrone, M.D.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Great Neck, New York • Hauppauge, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy

NCT01256632
View directory record Official record
Conditions
Choroidal Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
Vision Research Foundation
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

NCT00509795
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 4, 2026, 7:55 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

NCT01402544
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Results available

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

NCT00561834
View directory record Official record
Conditions
Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions
ranibizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Results available

Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

NCT01069341
View directory record Official record
Conditions
Rubeosis Iridis, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab
Drug
Lead sponsor
Bhagat, Neelakshi, M.D., M.P.H.
Individual
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

NCT00831350
View directory record Official record
Conditions
Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Lucentis in Advanced Macular Degeneration

NCT00896779
View directory record Official record
Conditions
Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Steven R. Sanislo
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 4, 2026, 7:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Ranibizumab With Mitomycin C During Trabeculectomy

NCT00661583
View directory record Official record
Conditions
Glaucoma
Interventions
Ranibizumab, Ranibizumab and MMC, MMC
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Oct 4, 2026, 7:55 PM EDT